Ratings by Morgan Stanley (Vikram Purohit)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/8/2026 | Genmab A/S | GMAB | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/18/2026 | Compass Pathways | CMPS | Maintain | Overweight (N/A) |
|
Details | ||
| 2/11/2026 | Incyte | INCY | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/6/2026 | Incyte | INCY | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/8/2025 | Incyte | INCY | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/5/2025 | Compass Pathways | CMPS | Maintain | Overweight (N/A) |
|
Details | ||
| 10/22/2025 | Incyte | INCY | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/30/2025 | Incyte | INCY | Maintain | Equalweight (N/A) |
|
Details | ||
| 6/17/2025 | Sage Therapeutics | SAGE | Maintain | Equalweight (N/A) |
|
Details | ||
| 6/16/2025 | Recursion Pharmaceuticals | RXRX | Maintain | Equalweight (N/A) |
|
Details | ||
| 6/3/2025 | Kymera Therapeutics | KYMR | Upgrade | Overweight (Equalweight) |
29.64 (44.44) |
49.93% | Details | |
| 5/7/2025 | Halozyme Therapeutics | HALO | Maintain | Overweight (N/A) |
|
Details | ||
| 5/5/2025 | Ascendis Pharma | ASND | Upgrade | Overweight (Equalweight) |
167.47 (172.00) |
2.7% | Details | |
| 4/23/2025 | Certara Inc. | CERT | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/10/2025 | Recursion Pharmaceuticals | RXRX | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/14/2025 | 2Seventy Bio Inc. | TSVT | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/12/2025 | Genmab A/S | GMAB | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/27/2025 | Axsome Therapeutics | AXSM | Maintain | Overweight (N/A) |
|
Details | ||
| 2/4/2025 | Ascendis Pharma | ASND | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/4/2025 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 12/11/2024 | Zenas Biopharma | ZBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 11/6/2024 | Kymera Therapeutics | KYMR | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/5/2024 | Sage Therapeutics | SAGE | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/30/2024 | Incyte | INCY | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/8/2024 | Zenas Biopharma | ZBIO | New Coverage | Overweight (N/A) |
18.81 (20.34) |
8.13% | Details | |
| 9/24/2024 | Foghorn Therapeutics | FHTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/4/2024 | Genmab A/S | GMAB | New Coverage | Equalweight (N/A) |
27.80 (26.00) |
-6.47% | Details | |
| 9/3/2024 | Recursion Pharmaceuticals | RXRX | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/3/2024 | Exscientia PLC | EXAI | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/23/2024 | Axsome Therapeutics | AXSM | Maintain | Overweight (N/A) |
|
Details | ||
| 8/21/2024 | Schrodinger | SDGR | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/19/2024 | Acelyrin Inc | SLRN | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/15/2024 | Ascendis Pharma | ASND | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/14/2024 | Kymera Therapeutics | KYMR | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/9/2024 | Certara Inc. | CERT | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/7/2024 | Halozyme Therapeutics | HALO | Maintain | Overweight (N/A) |
|
Details | ||
| 7/25/2024 | Sage Therapeutics | SAGE | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/3/2024 | Absci Corp. | ABSI | New Coverage | Overweight (N/A) |
3.01 (8.94) |
197.01% | Details | |
| 6/5/2024 | Compass Pathways | CMPS | Maintain | Overweight (N/A) |
|
Details | ||
| 5/15/2024 | Ascendis Pharma | ASND | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/2/2024 | Schrodinger | SDGR | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/29/2024 | Axsome Therapeutics | AXSM | Upgrade | Overweight (Equalweight) |
71.52 (103.91) |
45.29% | Details | |
| 4/26/2024 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/11/2024 | Abivax | ABVX | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/1/2024 | Compass Pathways | CMPS | New Coverage | Overweight (N/A) |
9.50 (13.25) |
39.47% | Details | |
| 3/1/2024 | Schrodinger | SDGR | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/29/2024 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Overweight (N/A) |
|
Details | ||
| 2/28/2024 | Sage Therapeutics | SAGE | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/23/2024 | Kymera Therapeutics | KYMR | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/23/2024 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 1/8/2024 | Kymera Therapeutics | KYMR | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/26/2023 | Halozyme Therapeutics | HALO | Maintain | Overweight (N/A) |
|
Details | ||
| 12/21/2023 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Overweight (N/A) |
|
Details | ||
| 11/29/2023 | Acelyrin Inc | SLRN | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/14/2023 | Abivax | ABVX | New Coverage | Equalweight (N/A) |
10.50 (6.80) |
-35.24% | Details | |
| 11/13/2023 | Schrodinger | SDGR | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/13/2023 | Kymera Therapeutics | KYMR | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/13/2023 | Foghorn Therapeutics | FHTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/13/2023 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Overweight (N/A) |
|
Details | ||
| 11/8/2023 | Ascendis Pharma | ASND | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/7/2023 | Ventyx Biosciences Inc | VTYX | Downgrade | Equalweight (Overweight) |
14.09 (14.00) |
-0.64% | Details | |
| 11/2/2023 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/1/2023 | Incyte | INCY | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/10/2023 | Exscientia PLC | EXAI | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/13/2023 | Acelyrin Inc | SLRN | Downgrade | Equalweight (Overweight) |
27.90 (2.27) |
-91.86% | Details | |
| 9/6/2023 | Ascendis Pharma | ASND | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/5/2023 | Acelyrin Inc | SLRN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/29/2023 | Regenxbio Inc. | RGNX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/29/2023 | Kymera Therapeutics | KYMR | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/10/2023 | Halozyme Therapeutics | HALO | Maintain | Overweight (N/A) |
|
Details | ||
| 8/10/2023 | Certara Inc. | CERT | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/9/2023 | Sage Therapeutics | SAGE | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/1/2023 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/28/2023 | 2Seventy Bio Inc. | TSVT | Downgrade | Equalweight (Overweight) |
9.46 (5.00) |
-47.15% | Details | |
| 7/27/2023 | Certara Inc. | CERT | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/26/2023 | Evelo Biosciences Inc | EVLO | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/13/2023 | Recursion Pharmaceuticals | RXRX | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/6/2023 | Foghorn Therapeutics | FHTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 6/29/2023 | Schrodinger | SDGR | Maintain | Equalweight (N/A) |
|
Details | ||
| 6/12/2023 | Axsome Therapeutics | AXSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 6/5/2023 | HOOKIPA Pharma Inc. | HOOK | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/30/2023 | Acelyrin Inc | SLRN | New Coverage | Overweight (N/A) |
19.27 (2.27) |
-88.22% | Details | |
| 5/22/2023 | Recursion Pharmaceuticals | RXRX | New Coverage | Equalweight (N/A) |
5.47 (3.22) |
-41.13% | Details | |
| 5/10/2023 | Halozyme Therapeutics | HALO | Maintain | Overweight (N/A) |
|
Details | ||
| 5/9/2023 | Sage Therapeutics | SAGE | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/9/2023 | Regenxbio Inc. | RGNX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/9/2023 | Kymera Therapeutics | KYMR | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/9/2023 | Axsome Therapeutics | AXSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/5/2023 | Schrodinger | SDGR | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/3/2023 | Incyte | INCY | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/28/2023 | Ascendis Pharma | ASND | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/27/2023 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/12/2023 | Incyte | INCY | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/12/2023 | Axsome Therapeutics | AXSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/12/2023 | Ascendis Pharma | ASND | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/12/2023 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Overweight (N/A) |
|
Details | ||
| 4/10/2023 | Exscientia PLC | EXAI | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/4/2023 | Ascendis Pharma | ASND | Downgrade | Equalweight (Overweight) |
107.22 (167.47) |
56.19% | Details | |
| 3/10/2023 | Schrodinger | SDGR | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/10/2023 | Foghorn Therapeutics | FHTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/10/2023 | Certara Inc. | CERT | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/6/2023 | Regenxbio Inc. | RGNX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/6/2023 | Halozyme Therapeutics | HALO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/1/2023 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Overweight (N/A) |
|
Details | ||
| 2/28/2023 | Axsome Therapeutics | AXSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/17/2023 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 2/15/2023 | Evelo Biosciences Inc | EVLO | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/28/2022 | Akili | AKLI | New Coverage | Equalweight (N/A) |
1.00 (0.43) |
-57% | Details | |
| 12/21/2022 | Halozyme Therapeutics | HALO | New Coverage | Overweight (N/A) |
56.20 (70.76) |
25.91% | Details | |
| 12/19/2022 | Kymera Therapeutics | KYMR | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/13/2022 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Overweight (N/A) |
|
Details | ||
| 12/9/2022 | Instil Bio Inc | TIL | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/29/2022 | Axsome Therapeutics | AXSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/4/2022 | Kymera Therapeutics | KYMR | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/4/2022 | Schrodinger | SDGR | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/3/2022 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 11/1/2022 | Instil Bio Inc | TIL | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/4/2022 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Overweight (N/A) |
|
Details | ||
| 9/26/2022 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Overweight (N/A) |
|
Details | ||
| 9/9/2022 | Schrodinger | SDGR | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/9/2022 | Exscientia PLC | EXAI | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/9/2022 | Evelo Biosciences Inc | EVLO | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/9/2022 | Talaris Therapeutics | TALS | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/9/2022 | Regenxbio Inc. | RGNX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/30/2022 | Axsome Therapeutics | AXSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/24/2022 | Schrodinger | SDGR | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/24/2022 | Certara Inc. | CERT | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/24/2022 | Exscientia PLC | EXAI | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/24/2022 | Instil Bio Inc | TIL | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/24/2022 | Evelo Biosciences Inc | EVLO | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/23/2022 | Foghorn Therapeutics | FHTX | Downgrade | Equalweight (Overweight) |
14.69 (4.10) |
-72.09% | Details | |
| 8/11/2022 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 8/10/2022 | Axsome Therapeutics | AXSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/2/2022 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Overweight (N/A) |
|
Details | ||
| 7/25/2022 | Theravance Biopharma | TBPH | Maintain | Underweight (N/A) |
|
Details | ||
| 7/8/2022 | Axsome Therapeutics | AXSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/5/2022 | Talaris Therapeutics | TALS | Downgrade | Equalweight (Overweight) |
4.51 (2.72) |
-39.69% | Details | |
| 6/13/2022 | Exscientia PLC | EXAI | Maintain | Equalweight (N/A) |
|
Details | ||
| 6/3/2022 | Instil Bio Inc | TIL | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/20/2022 | Foghorn Therapeutics | FHTX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2022 | Sage Therapeutics | SAGE | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/6/2022 | Axsome Therapeutics | AXSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/6/2022 | Certara Inc. | CERT | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/4/2022 | Incyte | INCY | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/4/2022 | Kymera Therapeutics | KYMR | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/20/2022 | Incyte | INCY | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/11/2022 | Exscientia PLC | EXAI | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/22/2022 | Regenxbio Inc. | RGNX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/22/2022 | Talaris Therapeutics | TALS | Maintain | Overweight (N/A) |
|
Details | ||
| 3/3/2022 | Certara Inc. | CERT | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/9/2022 | Incyte | INCY | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/19/2022 | Axsome Therapeutics | AXSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/15/2021 | Foghorn Therapeutics | FHTX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/10/2021 | Radius Health | RDUS | Downgrade | Underweight (Equalweight) |
8.01 (30.00) |
274.53% | Details | |
| 11/19/2021 | Schrodinger | SDGR | Downgrade | Equalweight (Overweight) |
44.45 (15.35) |
-65.47% | Details | |
| 11/12/2021 | HOOKIPA Pharma Inc. | HOOK | Downgrade | Equalweight (Overweight) |
4.35 (0.84) |
-80.69% | Details | |
| 11/11/2021 | Certara Inc. | CERT | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/8/2021 | Sage Therapeutics | SAGE | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/26/2021 | Exscientia PLC | EXAI | New Coverage | Equalweight (N/A) |
22.20 (4.84) |
-78.2% | Details | |
| 10/19/2021 | Sage Therapeutics | SAGE | New Coverage | Equalweight (N/A) |
44.07 (8.68) |
-80.3% | Details | |
| 10/19/2021 | Regenxbio Inc. | RGNX | New Coverage | Overweight (N/A) |
35.38 (10.67) |
-69.84% | Details | |
| 10/19/2021 | Kaleido Biosciences Inc. | KLDO | Downgrade | Underweight (Equalweight) |
4.94 (0.00) |
-100% | Details | |
| 9/23/2021 | Incyte | INCY | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/16/2021 | Theravance Biopharma | TBPH | Maintain | Underweight (N/A) |
|
Details | ||
| 9/7/2021 | Theravance Biopharma | TBPH | Maintain | Underweight (N/A) |
|
Details | ||
| 8/25/2021 | Theravance Biopharma | TBPH | Downgrade | Underweight (Overweight) |
14.17 (17.15) |
21.03% | Details | |
| 8/18/2021 | Kymera Therapeutics | KYMR | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/18/2021 | HOOKIPA Pharma Inc. | HOOK | Maintain | Overweight (N/A) |
|
Details | ||
| 8/10/2021 | Tscan Therapeutics Inc | TCRX | New Coverage | Overweight (N/A) |
10.46 (1.19) |
-88.62% | Details | |
| 8/10/2021 | Axsome Therapeutics | AXSM | Downgrade | Equalweight (Overweight) |
51.16 (244.53) |
377.97% | Details | |
| 7/16/2021 | Theravance Biopharma | TBPH | Maintain | Overweight (N/A) |
|
Details | ||
| 7/16/2021 | Kymera Therapeutics | KYMR | Maintain | Equalweight (N/A) |
|
Details | ||
| 6/1/2021 | Talaris Therapeutics | TALS | New Coverage | Overweight (N/A) |
15.12 (2.72) |
-82.01% | Details | |
| 5/26/2021 | Instil Bio Inc | TIL | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 5/26/2021 | Axsome Therapeutics | AXSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/18/2021 | Radius Health | RDUS | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 5/18/2021 | Kymera Therapeutics | KYMR | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 5/13/2021 | Theravance Biopharma | TBPH | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/4/2021 | Incyte | INCY | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/13/2021 | Instil Bio Inc | TIL | New Coverage | Equalweight (N/A) |
22.03 (7.62) |
-65.41% | Details | |
| 4/8/2021 | HOOKIPA Pharma Inc. | HOOK | New Coverage | Overweight (N/A) |
13.56 (0.84) |
-93.81% | Details | |
| 4/5/2021 | Incyte | INCY | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 3/22/2021 | Kymera Therapeutics | KYMR | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 3/22/2021 | Foghorn Therapeutics | FHTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/8/2021 | Certara Inc. | CERT | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 3/2/2021 | Axsome Therapeutics | AXSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/1/2021 | Theravance Biopharma | TBPH | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/25/2021 | Pandion Therapeutics | PAND | Downgrade | Equalweight (Overweight) |
25.63 (60.05) |
134.3% | Details | |
| 2/10/2021 | Incyte | INCY | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 1/19/2021 | Kymera Therapeutics | KYMR | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 1/6/2021 | Certara Inc. | CERT | New Coverage | Equalweight (N/A) |
33.00 (5.57) |
-83.12% | Details | |
| 11/9/2020 | Incyte | INCY | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/14/2020 | Theravance Biopharma | TBPH | Upgrade | Overweight (Equalweight) |
17.62 (14.17) |
-19.58% | Details | |
| 8/25/2020 | Radius Health | RDUS | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/6/2020 | Incyte | INCY | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/13/2020 | Radius Health | RDUS | Downgrade | Equalweight (Overweight) |
14.80 (30.00) |
102.7% | Details | |
| 5/12/2020 | Incyte | INCY | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/8/2020 | Portola Pharmaceuticals | PTLA | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/29/2020 | Incyte | INCY | Downgrade | Equalweight (Overweight) |
102.98 (107.92) |
4.8% | Details | |
| 4/1/2020 | Incyte | INCY | Upgrade | Overweight (Equalweight) |
72.17 (107.92) |
49.54% | Details | |
| 3/6/2020 | Radius Health | RDUS | Maintain | Overweight (N/A) |
|
Details | ||
| 3/3/2020 | Unum Therapeutics | UMRX | Downgrade | Equalweight (Overweight) |
0.67 (2.35) |
250.75% | Details | |
| 2/28/2020 | Portola Pharmaceuticals | PTLA | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/10/2020 | Portola Pharmaceuticals | PTLA | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/27/2019 | Unum Therapeutics | UMRX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/26/2019 | Neon Therapeutics | NTGN | Downgrade | Underweight (Overweight) |
1.35 (3.07) |
127.41% | Details | |
| 11/6/2019 | Portola Pharmaceuticals | PTLA | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/11/2019 | Radius Health | RDUS | Maintain | Overweight (N/A) |
|
Details | ||
| 9/5/2019 | Unum Therapeutics | UMRX | New Coverage | Overweight (N/A) |
1.69 (2.35) |
39.05% | Details | |
| 9/5/2019 | Radius Health | RDUS | New Coverage | Overweight (N/A) |
27.70 (30.00) |
8.3% | Details | |
| 9/5/2019 | Neon Therapeutics | NTGN | New Coverage | Overweight (N/A) |
2.55 (1.35) |
-47.06% | Details | |
| 9/5/2019 | Portola Pharmaceuticals | PTLA | New Coverage | Equalweight (N/A) |
28.40 (18.03) |
-36.51% | Details | |
| 9/5/2019 | DBV Technologies S.A | DBVT | New Coverage | Equalweight (N/A) |
9.42 (16.07) |
70.59% | Details |
